Details

Autor(en) / Beteiligte

• Li, Philip H.
• Watts, Timothy J.
• Lui, Mei-Shan
• Lau, Chak-Sing
• Chung, Ho-Yin

Titel

Recall Urticaria in Adalimumab Hypersensitivity

Ist Teil von

• The journal of allergy and clinical immunology in practice (Cambridge, MA), 2018-05, Vol.6 (3), p.1032-1033

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2018

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Hypersensitivity to adalimumab was suspected, and skin prick (SPT) and intradermal tests (IDT) with adalimumab (Humira; Abbott Laboratories, Lake Bluff, Illinois) were performed 1 month later on the volar surface of her left arm. “Recall” reactions (local reactions at distant sites of previous injections or exposure) can either be IgE or T-cell mediated.1 First described in 1994, IgE-mediated reactions are usually urticarial and occasionally reported to occur after skin tests with certain drugs or immunotherapy.2 The underlying mechanisms remain to be elucidated, but long-lasting changes such as locally increased accumulation or sensitivity of mast cells have been proposed. Progressive large local reactions in this case were compatible with IgE-mediated late phase allergic reactions.3 Mild injection site reactions with anti-TNF agents are common and usually wane over time because of induction of tolerance.4 However, worsening reactions or additional IgE-mediated features (such as urticaria, angioedema, respiratory or cardiovascular involvement) warrant further investigation before additional dosing or empirical premedication.